Targeting Pulmonary Hypertension: Elucidating Sophocarpine's Protective Role via Preclinical Models

Area of Science:

• Pharmacology
• Cardiovascular Research
• Cell Biology

Background:

• Pulmonary hypertension (PH) is a severe condition characterized by elevated pulmonary artery pressure, potentially leading to heart failure.
• Current treatments for PH are limited, highlighting the need for novel therapeutic agents.
• Sophocarpine (SOP) has demonstrated antioxidant, anti-inflammatory, and antifibrotic properties, suggesting its potential utility in PH treatment.

Purpose of the Study:

• To investigate the therapeutic effects of sophocarpine (SOP) on pulmonary hypertension (PH) using in vivo and in vitro models.
• To elucidate the underlying mechanisms by which SOP alleviates PH-induced pathology.

Main Methods:

• Established in vivo and in vitro models of PH.
• Administered varying concentrations of SOP to treated models.
• Utilized techniques including scratch assay, flow cytometry, Western blotting, pulmonary artery pressure measurement, biochemical analysis, ELISA, ultrasound, HE staining, and Masson's trichrome staining.

Main Results:

• SOP significantly reduced the inflammatory response and apoptosis associated with PH.
• Treatment with SOP led to a decrease in pulmonary artery pressure.
• SOP effectively restored the balance of pulmonary artery remodeling, alleviating PH symptoms.

Conclusions:

• Sophocarpine (SOP) demonstrates significant protective effects against pulmonary hypertension (PH) in experimental models.
• SOP alleviates key pathological features of PH, including inflammation, apoptosis, and vascular remodeling.
• SOP is a promising therapeutic candidate for the treatment of pulmonary hypertension.